We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-1.18%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$496M
AUM Growth
+$22M
Cap. Flow
+$34.5M
Cap. Flow %
6.96%
Top 10 Hldgs %
10.47%
Holding
461
New
27
Increased
142
Reduced
189
Closed
26

Top Buys

Rank Stock Value
1
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$3.17M
2
MPLX icon
MPLX
MPLX
+$3.04M
3
BLW icon
BlackRock Limited Duration Income Trust
BLW
+$2.79M
4
ABDC
Alcentra Capital Corp
ABDC
+$1.98M
5
BKCC
BlackRock Capital Investment Corporation
BKCC
+$1.92M

Top Sells

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$6.67M
2
ECC
Eagle Point Credit Company
ECC
+$5.43M
3
ANDX
Andeavor Logistics LP
ANDX
+$2.66M
4
FRA icon
BlackRock Floating Rate Income Strategies Fund
FRA
+$2.25M
5
MVC
MVC Capital, Inc.
MVC
+$1.95M

Sector Composition

Rank Sector Weight
1 Financials 24.1%
2 Real Estate 16.28%
3 Energy 14.42%
4 Healthcare 8.59%
5 Materials 8.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
176
BioMarin Pharmaceuticals
BMRN
$11.5B
$577K 0.12%
8,566
-1,447
-14% -$111K
IRWD icon
177
Ironwood Pharmaceuticals
IRWD
$611M
$574K 0.12%
66,816
-11,244
-14% -$109K
SAGE
178
DELISTED
Sage Therapeutics
SAGE
$559K 0.11%
3,984
-661
-14% -$111K
RARE icon
179
Ultragenyx Pharmaceutical
RARE
$2.65B
$518K 0.1%
12,118
-2,044
-14% -$111K
STML
180
DELISTED
Stemline Therapeutics, Inc.
STML
$509K 0.1%
48,906
-8,221
-14% -$108K
FOLD
181
DELISTED
Amicus Therapeutics
FOLD
$490K 0.1%
61,053
-10,267
-14% -$111K
ENTA icon
182
Enanta Pharmaceuticals
ENTA
$372M
$485K 0.1%
8,079
-1,354
-14% -$101K
ALLK
183
DELISTED
Allakos
ALLK
$472K 0.1%
6,003
-335
-5% -$22.1K
AGIO icon
184
Agios Pharmaceuticals
AGIO
$2.16B
$467K 0.09%
14,418
-2,429
-14% -$101K
SRPT icon
185
Sarepta Therapeutics
SRPT
$1.66B
$436K 0.09%
5,794
-976
-14% -$115K
KPTI icon
186
Karyopharm Therapeutics
KPTI
$168M
$426K 0.09%
2,950
-164
-5% -$22.2K
TVTX icon
187
Travere Therapeutics
TVTX
$5.33B
$418K 0.08%
36,097
-6,064
-14% -$100K
DCPH
188
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$400K 0.08%
11,793
-656
-5% -$19.4K
ALDR
189
DELISTED
Alder Biopharmaceuticals
ALDR
$396K 0.08%
20,985
-1,169
-5% -$13.4K
NKTR icon
190
Nektar Therapeutics
NKTR
$2.39B
$378K 0.08%
1,383
-248
-15% -$91K
LXRX icon
191
Lexicon Pharmaceuticals
LXRX
$1.02B
$369K 0.07%
122,654
-20,618
-14% -$63.8K
ACHN
192
DELISTED
Achillion Pharmaceuticals
ACHN
$326K 0.07%
90,554
-5,044
-5% -$19.4K
KRYS icon
193
Krystal Biotech
KRYS
$9.88B
$322K 0.06%
9,283
-517
-5% -$23.1K
THOR
194
DELISTED
Synthorx, Inc. Common Stock
THOR
$322K 0.06%
19,810
-1,099
-5% -$18.4K
PGNX
195
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$312K 0.06%
61,773
-3,441
-5% -$17.2K
GTHX
196
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$310K 0.06%
13,603
-757
-5% -$23.9K
IMGN
197
DELISTED
Immunogen Inc
IMGN
$309K 0.06%
127,596
-7,108
-5% -$18.9K
AMRS
198
DELISTED
Amyris Inc.
AMRS
$306K 0.06%
64,282
-3,581
-5% -$13.4K
CYTK icon
199
Cytokinetics
CYTK
$11B
$301K 0.06%
26,487
-1,475
-5% -$18.5K
EIDX
200
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$289K 0.06%
8,047
-448
-5% -$17.5K
6 7
8
9 10

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q3 2019 Portfolio in Review

As of Q3 2019, Virtus ETF Advisers held 461 positions worth $496M, up 4.6% from $474M the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Virtus ETF Advisers deployed $34.5M of net new capital in Q3 2019, opening 27 new positions and adding to 142 existing holdings. Its largest new stake was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.

By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 24% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was TriplePoint Venture Growth BDC, an estimated $813K trimmed.

  • Virtus ETF Advisers's largest Q3 2019 buy was INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND: 287,315 shares worth $3.16M.
  • Virtus ETF Advisers added most to MPLX in Q3 2019, an estimated $3.04M increase.
  • Virtus ETF Advisers's biggest Q3 2019 reduction was TriplePoint Venture Growth BDC, cutting an estimated $813K.
  • Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2019, selling an estimated $6.67M.
  • Virtus ETF Advisers's ten largest holdings make up 10% of its $496M portfolio in Q3 2019.
  • Virtus ETF Advisers opened 27 new positions and closed 26 in Q3 2019.
  • Virtus ETF Advisers's portfolio value rose 4.6% quarter-over-quarter to $496M.

Based on Virtus ETF Advisers's 13F filing for Q3 2019, filed 12 Nov 2019.